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Preamble
Guidelines and Expert Consensus Documents aim to
present all the relevant evidence on a particular issue in
order to help physicians to weigh the beneﬁts and risks
of a particular diagnostic or therapeutic procedure. They
should be helpful in everyday clinical decision-making.
A great number of Guidelines and Expert Consensus
Documents have been issued in recent years by the
European Society of Cardiology (ESC) and by different
organizations and other related societies. This profusion
can put at stake the authority and validity of guidelines,
which can only be guaranteed if they have been deve-
loped by an unquestionable decision-making process.
This is one of the reasons why the ESC and others have
issued recommendations for formulating and issuing
Guidelines and Expert Consensus Documents.
In spite of the fact that standards for issuing good
quality Guidelines and Expert Consensus Documents are
well deﬁned, recent surveys of Guidelines and Expert
Consensus Documents published in peer-reviewed jour-
nals between 1985 and 1998 have shown that methodo-
logical standards were not complied with in the vast
majority of cases. It is therefore of great importance
that guidelines and recommendations are presented in
formats that are easily interpreted. Subsequently, their
implementation programmes must also be well con-
ducted. Attempts have been made to determine
whether guidelines improve the quality of clinical prac-
tice and the utilization of health resources.
The ESC Committee for Practice Guidelines (CPG)
supervises and coordinates the preparation of new
Guidelines and Expert Consensus Documents produced
by Task Forces, expert groups, or consensus panels. The
chosen experts in these writing panels are asked to
provide disclosure statements of all relationships they
may have which might be perceived as real or potential
conﬂicts of interest. These disclosure forms are kept on
ﬁle at the European Heart House, headquarters of the
ESC. The Committee is also responsible for the endorse-
ment of these Guidelines and Expert Consensus
Documents or statements.
The Task Force has classiﬁed and ranked the usefulness
or efﬁcacy of the recommended procedure and/or treat-
ments and the Level of Evidence as indicated in the
tables on page 3.
Diagnosis of chronic heart failure
Introduction
Methodology
These Guidelines are based on the Diagnostic and
Therapeutic Guidelines published in 1995, 1997, and
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renewed in 2001,1–3 which has now been combined into
one manuscript. Where new information is available, an
update has been performed while other parts are
unchanged or adjusted only to a limited extent.
The aim of this report is to provide updated practical
guidelines for the diagnosis, assessment, and treatment
of heart failure for use in clinical practice, as well as
for epidemiological surveys and clinical trials. Particular
attention in this update has been allocated to diastolic
function and heart failure with preserved left ventricular
ejection fraction (PLVEF). The intention has been to
merge the previous Task Force report4 with the present
update.
The Guidelines are intended as a support for practising
physicians and other health care professionals concerned
with the management of heart failure patients and to
provide advice on how tomanage these patients, including
recommendations for referral. Documented and published
evidence ondiagnosis, efﬁcacy, and safety is themain basis
for these guidelines. ESC Guidelines are relevant to 49
member-states with diverse economies and therefore
recommendations based on cost-effectiveness have been
avoided in general. National health policy as well as clini-
cal judgement may dictate the order of priority of
implementation. It is recognized that some interventions
may not be affordable in some countries for all appropriate
patients. The recommendations in these guidelines should
therefore always be considered in the light of national
policies and local regulatory requirements for the admini-
stration of any diagnostic procedure, medicine, or device.
This report was drafted by a Writing Group of the Task
Force (see title page) appointed by the CPG of the ESC.
Within this Task Force, statements of Conﬂicts of
Interests were collected, which are available at the ESC
Ofﬁce. The draft was sent to the Committee and the
document reviewers (see title page) and after their
input the document was updated, reviewed and then
approved for presentation. The summary is based on a
full document, which includes more background state-
ments and includes references. This document is avai-
lable at the ESC website www.escardio.org. The full
report should be used when in doubt or when further
information is required. An evidenced based approach
to the evaluations has been applied including a grading
of the evidence for recommendations. However, for the
diagnosis, evidence is incomplete and in general based
on consensus of expert opinions. Already in the 2001
version, it was decided not to use evidence grading in
this part. The same approach has been used here.
Major conclusions or recommendations have been
highlighted by Bullets.
Epidemiology
. Much is now known about the epidemiology of heart
failure in Europe but the presentation and aetiology
are heterogeneous and less is known about differences
among countries.
The ESC represents countries with a population of over 900
million, suggesting that there are at least 10 million
patients with heart failure in those countries. There are
also patients with myocardial systolic dysfunction without
symptoms of heart failure and who constitute approxi-
mately a similar prevalence.5–7 The prognosis of heart
failure is uniformly poor if the underlying problem cannot
be rectiﬁed. Half of patients carrying a diagnosis of heart
failure will die within 4 years, and in patients with
severe heart failure .50% will die within 1 year.8,9 Many
patients with heart failure have symptoms and PLVEF.10
Studies show that the accuracy of diagnosis by clinical
means alone is often inadequate,11,12 particularly in
women, elderly, and obese. To study properly the epide-
miology and prognosis and to optimize the treatment of
heart failure, the uncertainty relating to the diagnosis
must be minimized or avoided completely.
Descriptive terms in heart failure
Acute vs. chronic heart failure
The term acute heart failure (AHF) is often used exclu-
sively to mean de novo AHF or decompensation of
chronic heart failure (CHF) characterized by signs of pul-
monary congestion, including pulmonary oedema. Other
forms include hypertensive AHF, pulmonary oedema,
cardiogenic shock, high output failure, and right heart
failure. (See Guidelines on acute heart failure.13)
CHF often punctuated by acute exacerbations, is the
most common form of heart failure. A deﬁnition of CHF
is suceedingly given.
Levels of evidence
Level of Evidence A Data derived from multiple
randomized clinical trials or
meta-analyses
Level of Evidence B Data derived from a single
randomized clinical trial
or large non-randomized studies
Level of Evidence C Consensus of opinion of the
experts and/or small studies,
reprospective studies, registries
Classes of recommendations
Class I Evidence and/or general agreement that a
given diagnostic procedure/treatment is
beneﬁcial, useful, and effective
Class II Conﬂicting evidence and/or a divergence of
opinion about the usefulness/efﬁcacy of the
treatment
Class IIa Weight of evidence/opinion is in favour of
usefulness/efﬁcacy
Class IIb Usefulness/efﬁcacy is less well established
by evidence/opinion
Class III Evidence or general agreement that the
treatment is not useful/effective and in
some cases may be harmful
Use of Class III is discouraged by the ESC.
ESC Guidelines 1117
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The present document will concentrate on the syn-
drome of CHF and leave out aspects on AHF.13 Thus,
heart failure, if not stated otherwise, is referring to the
chronic state.
Systolic vs. diastolic heart failure
Most heart failures are associated with evidence of left
ventricular systolic dysfunction, although diastolic
impairment at rest is a common if not universal accompa-
niment. In most cases, diastolic and systolic heart
failures should not be considered as separate patho-
physiological entities. Diastolic heart failure is often
diagnosed when symptoms and signs of heart failure
occur in the presence of a PLVEF (normal ejection frac-
tion) at rest. Predominant diastolic dysfunction is rela-
tively uncommon in younger patients but increases in
importance in the elderly. PLVEF is more common in
women, in whom systolic hypertension and myocardial
hypertrophy with ﬁbrosis are contributors to cardiac
dysfunction.10,14
Other descriptive terms in heart failure
Right and left heart failure refer to syndromes presenting
predominantly with congestion of the systemic or pul-
monary veins. The terms do not necessarily indicate
which ventricle is most severely damaged. High- and
low-output, forward and backward, overt, treated, and
congestive are other descriptive terms still in occasional
use; the clinical utility of these terms is descriptive
without etiological information and therefore of little
use in determining modern treatment for heart failure.
Mild, moderate, or severe heart failure is used as a
clinical symptomatic description, where mild is used for
patients who can move around with no important limita-
tions of dyspnea or fatigue, severe for patients who are
markedly symptomatic and need frequent medical atten-
tion and moderate for the remaining patient cohort.
Deﬁnition of chronic heart failure
. Heart failure should never be the only diagnosis.
Many deﬁnitions of CHF exist15–18 but highlight only
selective features of this complex syndrome. The diag-
nosis of heart failure relies on clinical judgement based
on a history, physical examination, and appropriate
investigations.
Heart failure is a syndrome in which the patients
should have the following features: symptoms of heart
failure, typically breathlessness or fatigue, either at
rest or during exertion, or ankle swelling and objective
evidence of cardiac dysfunction at rest (Table 1 ). The
distinctions between cardiac dysfunction, persistent
heart failure, heart failure that has been rendered
asymptomatic by therapy, and transient heart failure
are outlined in Figure 1. A clinical response to treatment
directed at heart failure alone is not sufﬁcient for diagno-
sis, although the patient should generally demonstrate
some improvement in symptoms and/or signs in response
to those treatments in which a relatively fast sympto-
matic improvement could be anticipated (e.g. diuretic
or nitrate administration).
Asymptomatic left ventricular systolic dysfunction
is considered as precursor of symptomatic CHF and is
Figure 1 Relationship between cardiac dysfunction, heart failure, and heart failure rendered asymptomatic.
Table 1 Deﬁnition of heart failure
I. Symptoms of heart failure (at rest or during exercise)
and
II. Objective evidence (preferably by echocardiography)
of cardiac dysfunction (systolic and/or diastolic)
(at rest) and (in cases where the diagnosis is in doubt)
and
III. Response to treatment directed towards heart failure
Criteria I. and II. should be fulﬁlled in all cases.
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associated with high mortality.19 It is important when
diagnosed and treatment is available, and the condition
is therefore included in these Guidelines.
Aspects of the pathophysiology of the
symptoms of heart failure relevant
to diagnosis
The origin of the symptoms of heart failure is not fully
understood. Increased pulmonary capillary pressure is
undoubtedly responsible for pulmonary oedema in part,
but studies conducted during exercise in patients with
CHF demonstrate only a weak relationship between
capillary pressure and exercise performance.20,21 This
suggests either that raised pulmonary capillary pressure
is not the only factor responsible for exertional breath-
lessness (e.g. lungwater and plasma albumin) or that
current techniques to measure true pulmonary capi-
llary pressure may not be adequate. Variation in the
degree of mitral regurgitation will also inﬂuence
breathlessness.
Possible methods for the diagnosis of heart
failure in clinical practice
Symptoms and signs in the diagnosis of
heart failure
. Symptoms and signs are important as they alert the
observer to the possibility that heart failure exists.
The clinical suspicion of heart failure must be con-
ﬁrmed by more objective tests particularly aimed at
assessing cardiac function (Figure 2 ).
Breathlessness, ankle swelling, and fatigue are the
characteristic symptoms and signs of heart failure but
may be difﬁcult to interpret, particularly in elderly
patients, in obese, and in women. It should be inter-
preted carefully and different modes (e.g. effort and
nocturnal) should be assessed.
Fatigue is also an essential symptom in heart failure.
The origins of fatigue are complex including low cardiac
output, peripheral hypoperfusion, skeletal muscle decon-
ditioning, and confounded by difﬁculties in quantifying
this symptom.
Peripheral oedema, raised venous pressure, and hepa-
tomegaly are the characteristic signs of congestion of
systemic veins.22,23 Clinical signs of heart failure should
be assessed in a careful clinical examination, including
observing, palpating, and auscultating the patient.
Symptoms and the severity of heart failure
. There is a poor relationship between symptoms and the
severity of cardiac dysfunction.10,24 However, symp-
toms may be related to prognosis particularly if persist-
ing after therapy.25
Once a diagnosis of heart failure has been established,
symptoms may be used to classify the severity of heart
failure and should be used to monitor the effects of
therapy. However, as noted subsequently, symptoms
cannot guide the optimal titration of neurohormonal
blockers. The New York Heart Association (NYHA) classiﬁ-
cation is in widespread use (Table 2 ). In other situations,
the classiﬁcation of symptoms into mild, moderate, or
severe is used. Patients in NYHA class I would have to
have objective evidence of cardiac dysfunction, have a
past history of heart failure symptoms and be receiving
treatment for heart failure in order to fulﬁl the basic
deﬁnition of heart failure.
Figure 2 Algorithm for the diagnosis of heart failure or left ventricular dysfunction.
ESC Guidelines 1119
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In acute myocardial infarction, the classiﬁcation
described by Killip26 has been used to describe symptoms
and signs.27 It is important to recognize the common dis-
sociation between symptoms and cardiac dysfunction.
Symptoms are also similar in patients across different
levels of ejection fraction.28 Mild symptoms should not
be equated with minor cardiac dysfunction.
Electrocardiogram
. A normal electrocardiogram (ECG) suggests that the
diagnosis of CHF should be carefully reviewed.
Electrocardiographic changes are common in patients sus-
pected of having heart failure whether or not the diagnosis
proves to be correct. An abnormal ECG, therefore, has
little predictive value for the presence of heart failure.
On the other hand, if the ECG is completely normal,
heart failure, especially due LV systolic dysfunction, is
unlikely. The presence of pathological Q-waves may
suggest myocardial infarction as the cause of cardiac
dysfunction. A QRS width .120 ms suggests that cardiac
dyssynchrony may be present and a target for treatment.
The chest X-ray
. Chest X-ray should be part of the initial diagnostic
work-up in heart failure. It is useful to detect cardio-
megaly and pulmonary congestion; however, it has
only predictive value in the context of typical signs
and symptoms and in abnormal ECG.
Haematology and biochemistry
Routine diagnostic evaluation of patients with CHF
includes: complete blood count (Hb, leukocytes, and
platelets), S-electrolytes, S-creatinine, S-glucose,
S-hepatic enzymes, and urinalysis. Additional tests to
evaluate thyroid function should be considered according
to clinical ﬁndings. In acute exacerbations, acute myo-
cardial infarction is excluded by myocardial speciﬁc
enzyme analysis.
Natriuretic peptides
. Plasma concentrations of certain natriuretic peptides
or their precursors, especially BNP and NT-proBNP, are
helpful in the diagnosis of heart failure.
. A low-normal concentration in an untreated patient
makes heart failure unlikely as the cause of symptoms.
. BNP and NT-proBNP have considerable prognostic
potential, although evaluation of their role in treat-
ment monitoring remains to be determined.
As the diagnostic potential of natriuretic peptides is less
clear cut when systolic function is normal, there is
increasing evidence that their elevation can indicate
diastolic dysfunction is present.29,30 Other common
cardiac abnormalities that may cause elevated natriure-
tic peptide levels include left ventricular hypertrophy,
valvular heart disease, acute or chronic ischaemia or
hypertension,31 and pulmonary embolism.32
In considering the use of BNP and NT-proBNP as diag-
nostic aids, it should be emphasized that a ‘normal’
value cannot completely exclude cardiac disease, but a
normal or low concentration in an untreated patient
makes heart failure unlikely as the cause of symptoms.
In clinical practice today, the place of BNP and NT-
proBNP is as ‘rule out’ tests to exclude signiﬁcant
cardiac disease. Particularly in primary care but also in
certain aspects of secondary care (e.g. the emergency
room and clinics.) The cost-effectiveness of the test
suggest that a normal result should obviate the need
for further cardiological tests such as in the ﬁrst
instance echocardiography as well as more expensive
investigations.33
Echocardiography
. Echocardiography is the preferred method for the
documentation of cardiac dysfunction at rest.
. The most important measurement of ventricular func-
tion is the left ventricular ejection fraction (LVEF) for
distinguishing patients with cardiac systolic dysfunction
from patients with preserved systolic function.
The access to and use of echocardiography is encouraged
for the diagnosis of heart failure. Transthoracic Doppler
echocardiography (TDE) is rapid, safe, and widely
available.
Assessment of LV diastolic function
Assessment of diastolic function may be clinically useful:
(1) to detect abnormalities of diastolic function in
patients who present with CHF and normal left ventri-
cular ejection fraction, (2) in determining prognosis in
heart failure patients, (3) in providing a non-invasive
estimate of left ventricular diastolic pressure, and (4)
in diagnosing constrictive pericarditis and restrictive
cardiomyopathy.
Diagnostic criteria of diastolic dysfunction
A diagnosis of primary diastolic heart failure requires
three conditions to be simultaneously satisﬁed: (1) pre-
sence of signs or symptoms of CHF, (2) presence of
Table 2 New York Heart Association classiﬁcation of heart
failure
Class I No limitation: ordinary physical exercise does not
cause undue fatigue, dyspnoea, or palpitations
Class II Slight limitation of physical activity: comfortable
at rest but ordinary activity results in fatigue,
palpitations, or dyspnoea
Class III Marked limitation of physical activity: comfortable
at rest but less than ordinary activity results in
symptoms
Class IV Unable to carry out any physical activity without
discomfort: symptoms of heart failure are present
even at rest with increased discomfort with any
physical activity
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normal or only mildly abnormal left ventricular systolic
function (LVEF  45–50%), and (3) evidence of abnormal
left ventricular relaxation, diastolic distensibility, or
diastolic stiffness.34 Furthermore, it is essential to
exclude pulmonary disease.35
At an early stage of diastolic dysfunction, there is typi-
cally a pattern of ‘impaired myocardial relaxation’ with a
decrease in peak transmitral E-velocity, a compensatory
increase in the atrial-induced (A) velocity and therefore
a decrease in the E/A ratio.
In patients with advanced cardiac disease, there may
be a pattern of ‘restrictive ﬁlling’, with an elevated
peak E-velocity, a short E-deceleration time, and a mark-
edly increased E/A ratio. The elevated peak E-velocity is
due to elevated left atrial pressure that causes an
increase in the early-diastolic transmitral pressure
gradient.36
In patients with an intermediate pattern between
impaired relaxation and restrictive ﬁlling the E/A ratio
and the deceleration time may be normal, a so-called
‘pseudonormalized ﬁlling pattern’. This pattern may be
distinguished from normal ﬁlling by the demonstration
of reduced peak E0-velocity by TDI.37
The three ﬁlling patterns ‘impaired relaxation’, ‘pseu-
donormalized ﬁlling’, and ‘restrictive ﬁlling’ represent
mild, moderate, and severe diastolic dysfunction,
respectively37 (Figure 3 ). Thus, by using the combined
assessment of transmitral blood ﬂow velocities and mitral
annular velocities, it becomes possible to perform staging
of diastolic dysfunction during a routine echocardio-
graphic examination. We still lack prospective outcome
studies that investigate if assessment of diastolic func-
tion by these criteria may improve management of
heart failure patients.
Transoesophageal echocardiography is not recom-
mended routinely and can only be advocated in patients
who have an inadequate echo window, in complicated
valvular patients, and in patients with suspected dysfunc-
tion of mechanical mitral valve prosthesis or when it is
mandatory to identify or exclude a thrombus in the
atrial appendage.
Repeated echocardiography can be recommended in
the follow-up of patients with heart failure only when
there is an important change in the clinical status
suggesting signiﬁcant improvement or deterioration in
cardiac function.
Additional non-invasive tests to be considered
In patients in whom echocardiography at rest has not
provided enough information and in patients with
coronary artery disease (e.g. severe or refractory CHF
and coronary artery disease), further non-invasive
imaging may include stress echocardiography, radio-
nuclide imaging, and cardiac magnetic resonance
imaging (CMR).
Cardiac magnetic resonance imaging (CMR)
. CMR is a versatile, highly accurate, and reproducible
imaging technique for the assessment of left and
right ventricular volumes, global function, regional
wall motion, myocardial thickness, thickening, myocar-
dial mass, and cardiac valves.38,39 The method is well
suited for detection of congenital defects, masses
and tumours, valvular, and pericardial disease.
Figure 3 The three ﬁlling patterns ‘impaired relaxation’, ‘pseudonormalised ﬁlling’, and ‘restrictive ﬁlling’ represent mild, moderate, and severe
diastolic dysfunction, respectively.37
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. Measurements of lung function are of little value in
diagnosing CHF. However, they are useful in excluding
respiratory causes of breathlessness. Spirometry can
be useful to evaluate the extent of obstructive
airways disease which is a common comorbidity in
patients with heart failure.
Exercise testing
. In clinical practice, exercise testing is of limited value
for the diagnosis of heart failure. However, a normal
maximal exercise test in a patient not receiving treat-
ment for heart failure excludes heart failure as a diag-
nosis. The main applications of exercise testing in CHF
are focused more on functional and treatment assess-
ment and on prognostic stratiﬁcation.
Invasive investigation
. Invasive investigation is generally not required to
establish the presence of CHF but may be important
in elucidating the cause or to obtain prognostic
information.
Cardiac catheterization
Coronary angiography should be considered in patients
with acute or acutely decompensated CHF and in patients
with severe heart failure (shock or acute pulmonary
oedema) who are not responding to initial treatment.
Coronary angiography should also be considered in
patients with angina pectoris or any other evidence of
myocardial ischaemia if they are not responding to appro-
priate anti-ischaemic treatment. Revascularization has
not been shown to alter prognosis in heart failure in
clinical trials and therefore, in the absence of angina
pectoris unresponsive to medical therapy, coronary
arteriography is not indicated. Coronary angiography
is also indicated in patients with refractory heart
failure of unknown aetiology and in patients with
evidence of severe mitral regurgitation or aortic valve
disease.
Monitoring of haemodynamic variables by means of a
pulmonary arterial catheter is indicated in patients who
are hospitalized for cardiogenic shock or to direct treat-
ment of patients with CHF not responding promptly to
initial and appropriate treatment. Routine right heart
catheterization should not be used to tailor chronic
therapy.
Tests of neuroendocrine evaluations other than
natriuretic peptides
. Tests of neuroendocrine activation are not rec-
ommended for diagnostic or prognostic purposes in
individual patients.
Holter electrocardiography: ambulatory ECG and
long-time ECG recording (LTER)
. Conventional Holter monitoring is of no value in the
diagnosis of CHF, though it may detect and quantify
the nature, frequency and duration of atrial and ventri-
cular arrhythmias which could be causing or exacer-
bating symptoms of heart failure. Recording LTER
should be restricted to patients with CHF and symp-
toms suggestive of an arrhythmia.
Requirements for the diagnosis of heart failure in
clinical practice
. To satisfy the deﬁnition of heart failure, symptoms of
heart failure and objective evidence of cardiac dysfunc-
tion must be present (Table 1 ). The assessment of
cardiac function by clinical criteria alone is unsatisfac-
tory. Cardiac dysfunction should be assessed objectively.
The echocardiogram is the single most effective tool in
widespread clinical use. Other conditions may mimic or
exacerbate the symptoms and signs of heart failure and
therefore need to be excluded (Table 3 ). An approach
(Figure 2 ) to the diagnosis of heart failure in sympto-
matic patients should be performed routinely in patients
with suspected heart failure in order to establish the
diagnosis. Additional tests (Table 4 ) should be performed
or re-evaluated in cases in which diagnostic doubt per-
sists or clinical features suggest a reversible cause for
heart failure.
Figure 2 represents a simpliﬁed plan for the evaluation
of a patient presenting with symptoms suggestive of
heart failure or signs giving suspicion of left ventricular
systolic dysfunction. Table 5 provides a management
outline connecting the diagnosis component of the guide-
lines with the treatment section.
Prognostication
. The problem of deﬁning prognosis in heart failure is
complex for many reasons: several aetiologies, fre-
quent comorbidities, limited ability to explore the
paracrine pathophysiological systems, varying indivi-
dual progression and outcome (sudden vs. progressive
heart failure death), and efﬁcacy of treatments.
Moreover, several methodological limitations weaken
many prognostic studies. The variables more consist-
ently indicated as independent outcome predictors
are reported in Table 6.
Treatment of heart failure
Aims of treatment in heart failure
(i) Prevention—a primary objective
a. Prevention and/or controlling of diseases leading
to cardiac dysfunction and heart failure.
b. Prevention of progression to heart failure once
cardiac dysfunction is established.
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(ii) Maintenance or improvement in quality of life
(iii) Improved survival
Prevention of heart failure
. The development of ventricular dysfunction and heart
failure may be delayed or prevented by treatment
of conditions leading to heart failure, in particular
in patients with hypertension and/or coronary
artery disease (Class of recommendation I, level of
evidence A).40
. The prevention of heart failure should always be a
primary objective.
When myocardial dysfunction is already present, the ﬁrst
objective is to remove the underlying cause of
ventricular dysfunction if possible (e.g. ischaemia, toxic
substances, alcohol, drugs, and thyroid disease), provid-
ing the beneﬁts of intervention outweigh the risks. When
the underlying cause cannot be corrected treatment
should be directed at delaying or preventing left ventri-
cular dysfunction that will increase the risk of sudden
death and the development of heart failure.
How to modulate progression from asymptomatic left
ventricular dysfunction to heart failure is described on
page 1133, Treatment of Asymptomatic Left Ventricular
Dysfunction.
Management of chronic heart failure
The therapeutic approach in patients with CHF that is
caused by left ventricular systolic dysfunction includes
Table 3 Assessments to be performed routinely to establish the presence and likely cause of heart failure
Assessments Diagnosis of heart failure Suggests alternative
or additional diagnosis
Necessary for Supports Opposes
Appropriate symptoms þþþ þþþ (If absent)
Appropriate signs þþþ þ (If absent)
Cardiac dysfunction on Imaging
(usually echocardiography)
þþþ þþþ (If absent)
Response of symptoms or signs
to therapy
þþþ þþþ (If absent)
ECG þþþ (If Normal)
Chest X-ray If pulmonary
congestion or
cardiomegaly
þ (If normal) Pulmonary disease
Full blood count Anaemia/secondary
polycythaemia






þ (If elevated) þþþ (If normal) Can be normal in
treated patients
þ ¼ of some importance; þþþ ¼ of great importance.
Table 4 Additional tests to be considered to support the diagnosis or to suggest alternative diagnoses
Tests Diagnosis of heart failure Suggests alternative or
additional diagnosis
Supports Opposes
Exercise test þ (If impaired) þþþ (If normal)
Pulmonary function tests Pulmonary disease










þþþ (If elevated at rest) þþþ (If normal; in absence
of therapy)
þ ¼ of some importance; þþþ ¼ of great importance.
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general advice and other non-pharmacological measures,
pharmacological therapy, mechanical devices, and
surgery. The currently available types of management
are outlined in Tables 5 and 7.
Non-pharmacological management
General advice and measures
(Class of recommendation I, level of evidence C for non-
pharmacological management unless stated otherwise)
Educating patients and family
Patients with CHF and their close relatives should receive
general advice.
Weight monitoring
Patients are advised to weigh on a regular basis to
monitor weight gain (preferably as part of a regular
daily routine, for instance after morning toilet) and,
in case of a sudden unexpected weight gain of .2 kg in
3 days, to alert a health care provider or adjust their
diuretic dose accordingly (e.g. to increase the dose if a
sustained increase in weight is noted).
Dietary measures
Sodium. Controlling the amount of salt in the diet is a
problem, that is, more important in advanced than in
mild heart failure.
Fluids. Instructions on ﬂuid control should be given to
patients with advanced heart failure, with or without
hyponatraemia. The exact amount of ﬂuid restriction
remains unclear, however. In practice, a ﬂuid restriction
of 1.5–2 L/day is advised in advanced heart failure.
Alcohol. Moderate alcohol intake (one beer, 1–2 glasses
of wine/day) is permitted other than in case of alcoholic





































































































































































































































































































































































































































































































































































































































































































































Table 5 Management outline
Establish that the patient has heart failure (in accordance with
the deﬁnition presented on page 1122, diagnosis section)
Ascertain presenting features: pulmonary oedema, exertional
breathlessness, fatigue, peripheral oedema
Assess severity of symptoms
Determine aetiology of heart failure
Identify precipitating and exacerbating factors
Identify concomitant diseases relevant to heart failure and its
management
Estimate prognosis based on page 1124, Table 6.
Assess complicating factors (e.g. renal dysfunction, arthritis)
Counsel patient and relatives
Choose appropriate management
Monitor progress and manage accordingly
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Treatment of CHF should include weight reduction in
obese patients.
Abnormal weight loss
Clinical or subclinical malnutrition is present in 50% of
patients with severe CHF. The wasting of total body fat
and lean body mass that accompanies weight loss is
called cardiac cachexia. Cardiac cachexia is an important
predictor of reduced survival.41
Smoking
Smoking should always be discouraged. The use of
smoking cessation aids should be actively encouraged
and may include nicotine replacement therapies.
Travelling
High altitudes or very hot or humid places should be dis-
couraged. In general, short air ﬂights are preferable to
long journeys by other means of transport.
Sexual activity
It is not possible to dictate guidelines about sexual
activity counselling. Recommendations are given to reas-
sure the not severely compromised, but frightened
patient, to reassure the partner who is often even more
frightened, and perhaps refer the couple for specialist
counselling. Little is known about the effects of treat-
ments for heart failure on sexual function.
Advice on immunizations
There is no documented evidence of the effects of immu-
nization in patients with heart failure. Immunization for
inﬂuenza is widely used.
Drug counselling
Self-management (when practical) of the dose of the
diuretic, based on changes in symptoms and weight
(ﬂuid balance), should be encouraged. Within pre-speci-
ﬁed and individualized limits, patients are able to
adjust their diuretics.
Drugs to avoid or beware
The following drugs should be used with caution when co-
prescribed with any form of heart failure treatment or
avoided:
(i) Non-steroidal anti-inﬂammatory drugs (NSAIDS) and
coxibs
(ii) Class I anti-arrhythmic agents (page 1131)
(iii) Calcium antagonists (verapamil, diltiazem, and




Rest, exercise, and exercise training
Rest
In acute heart failure or destabilization of CHF, physical
rest or bed rest is recommended.
Exercise
Exercise improves skeletal muscle function and therefore
overall functional capacity. Patients should be encouraged
and advised on how to carry out daily physical and leisure
time activities that do not induce symptoms. Exercise
training programs are encouraged in stable patients
in NYHA class II–III. Standardized recommendations
for exercise training in heart failure patients by the
European Society of Cardiology have been published.42
Pharmacological therapy
Angiotensin-converting enzyme inhibitors
. Angiotensin-converting enzyme (ACE) inhibitors are
recommended as ﬁrst-line therapy in patients with a
reduced left ventricular systolic function expressed as
a subnormal ejection fraction, i.e. ,40–45% with or
without symptoms (see non-invasive imaging; page
1121 Diagnosis section) (Class of recommendation I,
level of evidence A).
. ACE-inhibitors should be uptitrated to the dosages
shown to be effective in the large, controlled trials in
heart failure (Class of recommendation I, level of evi-
dence A), and not titrated based on symptomatic
improvement alone (Class of recommendation I, level
of evidence C).
ACE-inhibitors in asymptomatic left ventricular
dysfunction
. Asymptomatic patients with a documented left ventri-
cular systolic dysfunction should be treated with an
ACE-inhibitor to delay or prevent the development of
heart failure. ACE-inhibitors also reduce the risk of
Table 7 Treatment options: general advice and measures,
exercise and exercise training, pharmacological therapy,
and devices and surgery
Non-pharmacological management
General advice and measures














Revascularization (catheter interventions and/or surgery),
Other forms of surgery (mitral valve repair)
Bi-ventricular (multi-site) pacing
Implantable cardioverter deﬁbrillator (ICD)
Heart transplantation, ventricular assist devices, and
artiﬁcial heart
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myocardial infarction and sudden death in this setting
(Class of recommendation I, level of evidence A).43–46
ACE-inhibitors in symptomatic heart failure
. All patients with symptomatic heart failure that is
caused by systolic left ventricular dysfunction should
receive an ACE-inhibitor (Class of recommendation I,
level of evidence A).47
. ACE-inhibition improves survival, symptoms, functional
capacity, and reduces hospitalization in patients with
moderate and severe heart failure and left ventricular
systolic dysfunction.
. ACE-inhibitors should be given as the initial therapy in
the absence of ﬂuid retention. In patients with ﬂuid
retention, ACE-inhibitors should be given together
with diuretics (Class of recommendation I, level of evi-
dence B).47,48
. ACE inhibition should be initiated in patients with signs
or symptoms of heart failure, even if transient, after
the acute phase of myocardial infarction, even if the
symptoms are transient to improve survival and to
reduce reinfarctions and hospitalizations for heart
failure (Class of recommendation I, level of evidence
A).44,45,49
. Asymptomatic patients with a documented left ventri-
cular systolic dysfunction beneﬁt from long-term ACE-
inhibitor therapy (Class of recommendation I, level of
evidence A).43–46
. Important adverse effects associated with ACE-inhibi-
tors are cough, hypotension, renal insufﬁciency, hyper-
kalaemia, syncope, and angioedema. Angiotensin
receptor blockers may be used as an effective alterna-
tive in patients who develop cough or angioedema
on an ACE-inhibitor (Class of recommendation I, level
of evidence A). Changes in systolic and diastolic blood
pressure and increases in serum creatinine are usually
small in normotensive patients.
. ACE-inhibitor treatment is contra-indicated in the pre-
sence of bilateral renal artery stenosis and angioedema
during previous ACE-inhibitor therapy (Class of rec-
ommendation III, level of evidence A).
Target maintenance dose ranges of ACE-inhibitors shown
to be effective in various trials are given in Table 8.
Recommended initiating and maintenance dosages of
ACE-inhibitors which have been approved for the treat-
ment of heart failure in Europe are presented in Table 9.
The dose of ACE-inhibitors should always be initiated at
the lower dose level and titrated to the target dose. The
recommended procedures for starting an ACE-inhibitor
are given in Table 10.
Regular monitoring of renal function is recommended:
(1) before, 1–2 weeks after each dose increment, and at
3–6 months interval; (2) when the dose of an ACE-inhibi-
tor is increased or other treatments, which may affect
renal function, are added (e.g. aldosterone antagonist
or angiotensin receptor blocker), (3) in patients with
past or present renal dysfunction or electrolyte disturb-
ances more frequent measurements should be made, or
(4) during any hospitalization.
Diuretics
Loop diuretics, thiazides, and metolazone
. Diuretics are essential for symptomatic treatment
when ﬂuid overload is present and manifest as pulmon-
ary congestion or peripheral oedema. The use of diure-
tics results in rapid improvement of dyspnoea and
increased exercise tolerance (Class of recommendation
I, level of evidence A).50,51
. There are no controlled randomized trials that
have assessed the effect on symptoms or survival of
these agents. Diuretics should always be administered
in combination with ACE-inhibitors and beta-blockers
if tolerated (Class of recommendation I, level of
evidence C).
Detailed recommendations and major side effects are
outlined in Tables 11 and 12.
Potassium-sparing diuretics
. Potassium-sparing diuretics should only be prescribed
if hypokalaemia persists despite ACE inhibition, or in
severe heart failure despite the combination ACE
inhibition and low-dose spironolactone (Class of rec-
ommendation I, level of evidence C). In patients who
are unable to tolerate even low doses of aldosterone
Table 8 Doses of ACE-inhibitors shown to be effective in large, controlled trials of heart failure, or left ventricular dysfunction
Studies of mortality Drug Target dose Mean daily dose
Studies in CHF
CONSENSUS Trial Study Group, 198748 Enalapril 20 mg b.i.d. 18.4 mg
V-HeFT II, 1991161 Enalapril 10 mg b.i.d. 15.0 mg
The SOLVD Investigators, 1991162 Enalapril 10 mg b.i.d. 16.6 mg
ATLAS, 1999163 Lisinopril High dose: 32.5–35 mg daily
Low dose: 2.5—5 mg daily
Studies after MI LV dysfunction with or without HF
SAVE, 199244 Captopril 50 mg t.i.d. 127 mg
AIRE, 199349 Ramipril 5 mg b.i.d. (not available)
TRACE, 199545 Trandolapril 4 mg daily (not available)
1126 ESC Guidelines
 at Bibliotheque Fac de M






antagonists due to hyperkalaemia and renal dysfunc-
tion, amiloride or triamterenemay be used (Class of rec-
ommendation IIb, level of evidence C).
. Potassium supplements are generally ineffective in this
situation (Class of recommendation III, level of evi-
dence C).
. The use of all potassium-sparing diuretics should be
monitored by repeated measurements of serum creati-
nine and potassium. A practical approach is to measure
serum creatinine and potassium every 5–7 days after
initiation of treatment until the values are stable. -
Thereafter, measurements can be made every 3–6
months.
Beta-adrenoceptor antagonists
. Beta-blockers should be considered for the treatment
of all patients (in NYHA class II–IV) with stable, mild,
moderate, and severe heart failure from ischaemic or
non-ischaemic cardiomyopathies and reduced LVEF on
standard treatment, including diuretics, and ACE-
inhibitors, unless there is a contraindication (Class of
recommendation I, level of evidence A).52–58
. Beta-blocking therapy reduces hospitalizations (all,
cardiovascular, and heart failure), improves the func-
tional class and leads to less worsening of heart
failure. This beneﬁcial effect has been consistently
observed in subgroups of different age, gender, func-
tional class, LVEF, and ischaemic or non-ischaemic
aetiology (Class of recommendation I, level of
evidence A).
. In patients with left ventricular systolic dysfunction,
with or without symptomatic heart failure, following
an acute myocardial infarction long-term beta-block-
ade is recommended in addition to ACE inhibition to
reduce mortality (Class of recommendation I, level of
evidence B).59
. Differences in clinical effects may be present between
different beta-blockers in patients with heart
failure.60,61 Accordingly, only bisoprolol, carvedilol,
metoprolol succinate and nebivolol can be rec-
ommended (Class of recommendation I, level of evi-
dence A).
Initiation of therapy
The initial dose should be small and increased slowly and
progressively to the target dose used in the large clinical
trials. Up-titration should be adapted to individual
responses.
Table 9 Recommended ACE-inhibitor maintenance dose
ranges for some agents approved for heart failure in Europe
Drug Initiating dose Maintenance
dose
Documented effects on mortality/hospitalization
Captopril 6.25 mg t.i.d. 25–50 mg t.i.d.
Enalapril 2.5 mg daily 10 mg b.i.d.




Trandolapril 1 mg daily 4 mg daily
Manufacturers’ or regulatory recommendations.
Table 10 The recommended procedure for starting an
ACE-inhibitor or an angiotensin receptor blocker
Review the need for and dose of diuretics and vasodilators
Avoid excessive diuresis before treatment. Consider reducing
or withholding diuretics, if being used, for 24 h
It may be advisable to start treatment in the evening, when
supine, to minimize the potential negative effect on blood
pressure, although there are no data in heart failure to
support this (Level of Evidence C). When initiated in the
morning, supervision for several hours with blood pressure
control is advisable in risk patients with renal dysfunction
or low blood pressure
Start with a low dose (Table 9 ) and build-up to maintenance
dosages shown to be effective in large trials (Table 8 )
If renal function deteriorates substantially, stop treatment
Avoid potassium-sparing diuretics during initiation of therapy
Avoid NSAIDs and coxibs
Check blood pressure, renal function, and electrolytes
1–2 weeks after each dose increment, at 3 months, and
subsequently at 6 regular monthly intervals
The following patients should be referred for specialist care:
Cause of heart failure unknown
Systolic blood pressure ,100 mmHg
Serum creatinine .150 mmol/L
Serum sodium ,135 mmol/L
Severe heart failure
Valve disease as primary cause
Table 11 Diuretics
Initial diuretic treatment
Loop diuretics or thiazides. Always administered
in addition to an ACE-inhibitor
If GFR ,30 mL/min, do not use thiazides, except as
therapy prescribed synergistically with loop diuretics
Insufﬁcient response:
Increase dose of diuretic
Combine loop diuretics and thiazides
With persistent ﬂuid retention: administer loop diuretics
twice daily
In severe heart failure add metolazone with frequent
measurement of creatinine and electrolytes
Potassium-sparing diuretics: triamterene, amiloride and
spironolactone
Use only if hypokalaemia persists after initiation of
therapy with ACE, inhibitors and diuretics
Start one-week low-dose administration; check serum
potassium and creatinine after 5–7 days and titrate
accordingly. Recheck every 5–7 days until potassium
values are stable
GFR ¼ glomerular ﬁltration rate.
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During titration, beta-blockers may reduce heart rate
excessively, temporarily induce myocardial depression,
and exacerbate symptoms of heart failure. Table 13
gives the recommended procedure for the use of beta-
blockers in clinical practice and contraindications.
Table 14 shows the titration scheme of the drugs used
in the most relevant studies.
Aldosterone receptor antagonists
. Aldosterone antagonists are recommended in addition
to ACE-inhibitors, beta-blockers and diuretics in
advanced heart failure (NYHA III–IV) with systolic dys-
function to improve survival and morbidity (Class of
recommendation I, level of evidence B).62
. Aldosterone antagonists are recommended in addition
to ACE-inhibitors and beta-blockers in heart failure
after myocardial infarction with left ventricular systo-
lic dysfunction and signs of heart failure or diabetes
to reduce mortality and morbidity (Class of recommen-
dation I, level of evidence B).63
Administration and dosing considerations for aldosterone
antagonists are provided in Table 15.
Angiotensin II receptor blockers
For patients with left ventricular systolic dysfunction:
. Angiotensin II receptor blockers (ARBs) can be used as
an alternative to ACE inhibition in symptomatic
patients intolerant to ACE-inhibitors to improve mor-
bidity and mortality (Class of recommendation I, level
of evidence B).64–67
. ARBs and ACE-inhibitors seem to have similar efﬁcacy in
CHF on mortality and morbidity (Class of recommen-
dation IIa, level of evidence B). In acute myocardial
infarction with signs of heart failure or left ventricular
dysfunction ARBs and ACE-inhibitors have similar or
equivalent effects on mortality (Class of recommen-
dation I, level of evidence B).68
. ARBs can be considered in combination with ACE-inhibi-
tors in patients who remain symptomatic, to reduce mor-
tality (Class of recommendation IIa, level of evidence B)
and hospital admissions for heart failure (Class of
recommendation I, level of evidence A).65,69–71,170
In NYHA class III patients remaining symptomatic despite
therapy with diuretics, ACE-inhibitors, and beta-block-
ers, there is no deﬁnite evidence for the recommen-
dation of next addition; an ARB or an aldosterone
antagonist to reduce further heart failure hospitaliz-
ations or mortality.
Concerns raised by initial studies about a potential
negative interaction between ARBs and beta-blockers
have not been conﬁrmed by recent studies in post-
myocardial infarction or CHF (Class of recommendation
I, level of evidence A).65,68
Dosing
Initiation and monitoring of ARBs, which are outlined in
Table 10, are similar to procedures for ACE-inhibitors.
Available ARBs and the recommended dose levels are
shown in Table 16.
Cardiac glycosides
. Cardiac glycosides are indicated in atrial ﬁbrillation
and any degree of symptomatic heart failure,
whether or not left ventricular dysfunction is the
cause. Cardiac glycosides slow the ventricular rate,
which improves ventricular function and symptoms
(Class of recommendation I, level of evidence B).72
. A combination of digoxin and beta-blockade
appears superior to either agent alone in patients







Furosemide 20–40 250–500 Hypokalaemia, hypomagnesaemia,
hyponatraemia
Bumetanide 0.5–1.0 5–10 Hyperuricaemia, glucose intolerance
Torasemide 5–10 100–200 Acid–base disturbance
Thiazides
Bendroﬂumethiazide 2.5 10
Hydrochlorothiazide 25 50–75 Hypokalaemia, hypomagnesaemia,
hyponatraemia
Metolazone 2.5 10 Hyperuricaemia, glucose intolerance
Indapamide 2.5 2.5 Acid–base disturbance
Potassium-sparing diuretic þACEI 2ACEI þACEI 2ACEI
Amiloride 2.5 5 20 40 Hyperkalaemia, rash
Triamterene 25 50 100 200 Hyperkalaemia
Spironolactone 12.5–25 50 50 100–200 Hyperkalaemia, gynaecomastia
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with atrial ﬁbrillation (Class of recommendation
IIa, level of evidence B).73
Digoxin has no effect on mortality but may
reduce hospitalizations and, particularly, wor-
sening heart failure hospitalizations, in the
patients with heart failure caused by left ventri-
cular systolic dysfunction and sinus rhythm
treated with ACE-inhibitors, beta-blockers,
diuretics and in severe heart failure, spironolac-
tone (Class of recommendation IIa, level of evi-
dence A).
. Contraindications to the use of cardiac glycosides
include bradycardia, second- and third-degree
AV block, sick sinus syndrome, carotid sinus
syndrome, Wolff–Parkinson–White syndrome,
hypertrophic obstructive cardiomyopathy, hypo-
kalaemia, and hyperkalaemia.
Digoxin
The usual daily dose of oral digoxin is 0.125–0.25 mg if
serum creatinine is in the normal range (in the elderly
0.0625–0.125 mg, occasionally 0.25 mg).
Vasodilator agents in chronic heart failure
. There is no speciﬁc role for direct-acting vasodilator
agents in the treatment of CHF (Class of recommen-
dation III, level of evidence A) though they may be
used as adjunctive therapy for angina or concomitant
hypertension (Class of recommendation I, level of evi-
dence A).
Hydralazine-isosorbide dinitrate
. In case of intolerance for ACE-inhibitors and ARBs, the
combination hydralazine/nitrates can be tried to
Table 13 The recommended procedure for starting a beta-blocker
I Patients should be on a background therapy with ACE inhibition, if not contraindicated
II The patient should be in a relatively stable condition, without the need of intravenous inotropic therapy and without signs of
marked ﬂuid retention
III Start with a very low dose and titrate up to maintenance dosages shown to be effective in large trials. The dose may be doubled
every 1–2 weeks if the preceding dose was well tolerated. Most patients can be managed as out-patients
IV Transient worsening failure, hypotension, or bradycardia may occur during the titration period or thereafter
a. Monitor the patient for evidence of heart failure symptoms, ﬂuid retention, hypotension, and symptomatic bradycardia
b. If worsening of symptoms, ﬁrst increase the dose of diuretics, or ACE-inhibitor; temporarily reduce the dose of
beta-blockers if necessary
c. If hypotension, ﬁrst reduce the dose of vasodilators; reduce the dose of the beta-blocker if necessary
d. Reduce or discontinue drugs that may lower heart rate in presence of bradycardia; reduce dose of beta-blockers if
necessary, but discontinue only if clearly necessary
e. Always consider the reintroduction and/or uptitration of the beta-blocker when the patient becomes stable
If inotropic support is needed to treat a decompensated patient on beta-blockade, phosphodiesterase inhibitors should be preferred
because their haemodynamic effects are not antagonized by beta-blocker agents
The following patients should be referred for specialist care:
a. Severe heart failure Class III/IV
b. Unknown aetiology
c. Relative contraindications: asymptomatic bradycardia, and/or low blood pressure
d. Intolerance to low doses
e. Previous use of beta-blocker and discontinuation because of symptoms
f. Suspicion of bronchial asthma or severe pulmonary disease
Contraindications to beta-blockers in patients with heart failure
g. Asthma bronchiale
h. Severe bronchial disease
i. Symptomatic bradycardia or hypotension
Table 14 Initiating dose, target dose, and titration scheme of beta-blocking agents as used in recent large, controlled trials
Beta-blocker First dose (mg) Increments (mg/day) Target dose (mg/day) Titration period
Bisoprolol164 1.25 2.5, 3.75, 5, 7.5, 10 10 Weeks–month
Metoprolol succinate CR165 12.5/25 25, 50, 100, 200 200 Weeks–month
Carvedilol54 3.125 6.25, 12.5, 25, 50 50 Weeks–month
Nebivolol58 1.25 2.5, 5, 10 10 Weeks–month
Daily frequency of administration as in the trials referenced here.
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reduce mortality and morbidity and improved quality
of life (Class of recommendation IIa, level of
evidence B).74
Nitrates
. Nitrates may be used for the treatment of concomitant
angina or relief of dyspnoea. (Class of recommendation
IIa, level of evidence C). Evidence that oral nitrates
improve symptoms of heart failure chronically or
during an acute exacerbation is lacking.
Alpha-adrenergic blocking drugs
. There is no evidence to support the use of alpha-
adrenergic blocking drugs in heart failure (Class of rec-
ommendation III, level of evidence B).75
Calcium antagonists
. Calcium antagonists are not recommended for the
treatment of heart failure caused by systolic dysfunc-
tion. Diltiazem- and verapamil-type calcium antagon-
ists, in particular, are not recommended in heart
failure because of systolic dysfunction; they are
contraindicated in addition to beta-blockade (Class of
recommendation III, level of evidence C).76,77
. Addition of newer calcium antagonists (felodipine and
amlodipine) to standard treatment for heart failure
does not improve symptoms and does not impact on
survival (Class of recommendation III, level of
evidence A).76,77
As long-term safety data with felodipine and amlodipine
indicate a neutral effect on survival, they may offer a
safe alternative for the treatment of concomitant arter-
ial hypertension or angina not controlled by nitrates and
beta-blockers.
Nesiritide
Nesiritide, a recombinant human brain or B-type
natriuretic peptide (BNP), has been shown to be efﬁca-
cious in improving subjective dyspnoea score as well as
inducing signiﬁcant vasodilation when administered
intravenous to patients with acute heart failure.
Clinical experience with nesiritide is still limited.
Nesiritide may cause hypotension and some patients are
non-responders.
Positive inotropic therapy
. Repeated or prolonged treatment with oral inotropic
agents increases mortality and is not recommended in
CHF (Class of recommendation III, level of evidence A).
. Intravenous administration of inotropic agents is com-
monly used in patients with severe heart failure with
signs of both pulmonary congestion and peripheral
hypoperfusion. However, treatment-related compli-
cations may occur and their effect on prognosis is
uncertain. Depending on agent level of evidence and
strength of recommendation varies.13
. Preliminary data suggests that some calcium sensitizers
(e.g. levosimendan) may have beneﬁcial effects on
symptoms and end-organ function and are safe.78
Anti-thrombotic agents
. In CHF associated with atrial ﬁbrillation, a previous
thromboembolic event or a mobile left ventricular
thrombus, anti-coagulation is ﬁrmly indicated (Class
of recommendation I, level of evidence A).79
. There is little evidence to show that anti-thrombotic
therapy modiﬁes the risk of death or vascular events
in patients with heart failure.
. After a prior myocardial infarction, either aspirin or
oral anti-coagulants are recommended as secondary
prophylaxis (Class of recommendation IIa, level of evi-
dence C).80
. Aspirin should be avoided in patients with recurrent
hospitalization with worsening heart failure (Class of
recommendation IIb, level of evidence B). Because of
the potential for increased bleeding complications,
anti-coagulant therapy should be administered under
the most controlled conditions, planning monitoring
in properly managed anti-coagulation clinics.
Table 16 Currently available angiotensin II receptor
antagonists
Drug Daily dose (mg)








Table 15 Administration and dosing considerations with
aldosterone antagonists (spironolactone, eplerenone)
. Consider whether a patient is in severe heart failure (NYHA
III–IV) despite ACE-inhibition/diuretics
. Check serum potassium (,5.0 mmol/L) and creatinine
(,250 mmol/L)
. Add a low dose (spironolactone 12.5–25 mg, eplerenone
25 mg) daily
. Check serum potassium and creatinine after 4–6 days
. If at any time serum potassium 5–5.5 mmol/L, reduce dose
by 50%. Stop if serum potassium .5.5 mmol/L
. If after 1 month symptoms persist and normokalaemia
exists, increase to 50 mg daily. Check serum potassium/
creatinine after 1 week
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Patients with CHF are at high risk of thromboembolic
events. Factors predisposing to thromboembolism are
low cardiac output with relative stasis of blood in
dilated cardiac chambers, poor contractility, regional
wall motion abnormalities, and atrial ﬁbrillation.
There is little evidence to support the concomitant
treatment with an ACE-inhibitor and aspirin in heart
failure.81–83
In general, the rates of thromboembolic complications
in heart failure are sufﬁciently low to limit the evaluation
of any potential beneﬁcial effect of anti-coagulation/
anti-thrombotic therapy in these patients.
Anti-arrhythmics
Anti-arrhythmic drugs other than beta-blockers are
generally not indicated in patients with CHF. In patients
with atrial ﬁbrillation (rarely ﬂutter), non-sustained, or
sustained ventricular tachycardia treatment with anti-
arrhythmic agents may be indicated.
Class I anti-arrhythmics
. Class I anti-arrhythmics should be avoided as they
may provoke fatal ventricular arrhythmias, have an
adverse haemodynamic effect and reduce survival
in heart failure (Class of recommendation III, level of
evidence B).84
Class II anti-arrhythmics
. Beta-blockers reduce sudden death in heart failure
(Class of recommendation I, level of evidence A) (see
also page 1127).85 Beta-blockers may also be indicated
alone or in combination with amiodarone or non-
pharmacological therapy in the management of sus-
tained or non-sustained ventricular tachy-arrhythmias
(Class of recommendation IIa, level of evidence C).86
Class III anti-arrhythmics
. Amiodarone is effective against most supraventricular
and ventricular arrhythmias (Class of recommendation
I, level of evidence A). It may restore and maintain
sinus rhythm in patients with heart failure and atrial
ﬁbrillation even in the presence of enlarged left
atria, or improve the success of electrical cardioversion
and amiodarone is the preferred treatment in this
condition.87,88 Amiodarone is the only anti-arrhythmic
drug without clinically relevant negative inotropic
effects.
Routine administration of amiodarone in patients with
heart failure is not justiﬁed (Class of recommendation
III, level of evidence A).89,90
Oxygen therapy
. Oxygen is used for the treatment of AHF, but in general
has no application in CHF (Class of recommendation III,
level of evidence C).
Surgery and devices
Revascularization procedures, mitral valve
surgery, and ventricular restoration
. If clinical symptoms of heart failure are present,
surgically correctable pathologies must always be
considered (Class of recommendation I, level of evi-
dence C).
Revascularization
. There are no data from multicenter trials to support
the use of revascularization procedures for the relief
of heart failure symptoms. Single centre, observational
studies on heart failure of ischaemic origin, suggest
that revascularization might lead to symptomatic
improvement (Class of recommendation IIb, level of
evidence C).
. Until the results of randomized trials are reported,
revascularization (surgical or percutaneous) is not rec-
ommended as routine management of patients with
heart failure and coronary disease (Class of recommen-
dation III, level of evidence C).
Mitral valve surgery
. Mitral valve surgery in patients with severe left ventri-
cular systolic dysfunction and severe mitral valve insuf-
ﬁciency due to ventricular insufﬁency may lead to
symptomatic improvement in selected heart failure
patients (Class of recommendation IIb, level of evi-
dence C). This is also true for secondary mitral insufﬁ-
ciency due to left ventricular dilatation.
Left ventricular restoration
LV aneurysmectomy
. LV aneurysmectomy is indicated in patients with large,
discrete left ventricular aneurysms who develop
heart failure (Class of recommendation I, level of evi-
dence C).
Cardiomyoplasty
. Currently, cardiomyoplasty cannot be recommended
for the treatment of heart failure (Class of recommen-
dation III, level of evidence C).
. Cardiomyoplasty cannot be considered a viable
alternative to heart transplantation (Class of rec-
ommendation III, level of evidence C).
Partial left ventriculectomy (Batista operation)
. Partial left ventriculectomy cannot be recommended
for the treatment of heart failure (Class of recommen-
dation I, level of evidence C). Furthermore, the Batista
operation should not be considered an alternative to
heart transplantation (Class of recommendation III,
level of evidence C).
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. Currently, external ventricular restoration cannot be
recommended for the treatment of heart failure.
Preliminary data suggest an improvement in LV dimen-
sions and NYHA class with some devices (Class of rec-
ommendation IIb, level of evidence C).
Pacemakers
. Pacemakers have been used in patients with heart
failure to treat bradycardia when conventional indi-
cations exist. Pacing only of the right ventricle in
patients with systolic dysfunction will induce ventricu-
lar dyssynchrony and may increase symptoms (Class of
recommendation III, level of evidence A).
. Resynchronization therapy using bi-ventricular pacing
can be considered in patients with reduced ejection
fraction and ventricular dyssynchrony (QRS width
120 ms) and who remain symptomatic (NYHA III–IV)
despite optimal medical therapy to improve symptoms
(Class of recommendation I, level of evidence A), hos-
pitalizations (Class of recommendation I, level of evi-
dence A) and mortality (Class of recommendation I,
level of evidence B).
Bi-ventricular pacing improves symptoms, exercise
capacity, and reduces hospitalizations.91–94 A beneﬁcial
effect on the composite of long-term mortality or all-
cause hospitalization has recently been demonstrated,
as well as a signiﬁcant effect on mortality.171
Implantable cardioverter deﬁbrillators
. Implantation of an implantable cardioverter deﬁbrilla-
tors (ICD) in combination with bi-ventricular pacing can
be considered in patients who remain symptomatic
with severe heart failure NYHA class III–IV with
LVEF  35% and QRS duration  120 ms to improve mor-
tality or morbidity (Class of recommendation IIa, level
of evidence B).93
. ICD therapy is recommended to improve survival in
patients who have survived cardiac arrest or who have
sustained ventricular tachycardia, which is either
poorly tolerated or associated with reduced systolic
left ventricular function (Class of recommendation I,
level of evidence A).95
. ICD implantation is reasonable in selected patients with
LVEF , 30–35%, not within 40 days of a myocardial
infarction, on optimal background therapy including
ACE-inhibitor, ARB, beta-blocker, and an aldosterone
antagonist, where appropriate, to reduce sudden
death (Class of recommendation I, level of evidence
A).90,96,97
In patients with documented sustained ventricular tachy-
cardia or ventricular ﬁbrillation, the ICD is highly effec-
tive in treating recurrences of these arrhythmias, either
by anti-tachycardia pacing or cardioversion/deﬁbrilla-
tion, thereby reducing morbidity and the need for
rehospitalization. The selection criteria, the limited
follow-up and increased morbidity associated with ICD-
implantation and the low cost-effectiveness make it
inappropariate to extend the ﬁndings into a general
population with CHF. The COMPANION trial included
patients with left ventricular systolic dysfunction, wide
QRS complex suggesting dyssynchrony and heart failure
and showed that implantation of an ICD in combination
with resynchronization in patients with severe heart
failure reduced mortality and morbidity (See under
Resynchronization).93 However, CRT-D was not superior
to CRTalone in terms of reducing mortality and therefore
the treatment associated with lower morbidity and cost
may be preferred for the majority of patients. CRT-D
should be reserved for patients considered at very high
risk of sudden death despite medical treatment and
CRT alone. The cost-effectiveness of this treatment
needs to be established.98 In the SCD-HeFT trial, 2521
patients with CHF and LVEF  35% were randomized to
placebo, amiodarone, or single-lead ICD implantation.
After a median follow-up of 45.5 months, there was a sig-
niﬁcant reduction in mortality by ICD therapy; HR 0.77
(97.5% CI: 0.62–0.96; P ¼ 0.007).90 There was no diffe-
rence between placebo and amiodarone on survival.
Several recent meta-analyses estimated the effect of
ICD implantation on all-cause mortality in symptomatic
patients with reduced ejection fraction.83,99,100 As the
effectiveness with ICD is time-dependent,101 anticipated
duration of treatment is important to establish cost-
effectiveness. Accordingly, the age of the patient and
non-cardiac comorbidity must also be taken into
account. Treatment of patients in NYHA class IV is not
well established unless associated with CRT in the
context of dyssynchrony. There is no evidence that
patients with DCM obtain proportionally less beneﬁt but
as the prognosis of this group is generally better, the
absolute beneﬁts may be less.83
Heart replacement therapies: heart
transplantation, ventricular assist devices,
and artiﬁcial heart
Heart transplantation
. Heart transplantation is an accepted mode of treatment
for end stage heart failure. Although controlled trials
have never been conducted, it is considered to signiﬁ-
cantly increase survival, exercise capacity, return to
work and quality of life compared with conventional
treatment, provided proper selection criteria are
applied (Class of recommendation I, level of evidence C).
Patients who should be considered for heart transplan-
tation are those with severe symptoms of heart failure
with no alternative form of treatment and with a poor
prognosis. The introduction of new treatments has prob-
ably modiﬁed the prognostic signiﬁcance of the variables
traditionally used to identify heart transplant candidates
i.e. VO2 max (see prognostication page 1122). The
patient must be willing and capable to undergo intensive
medical treatment, and be emotionally stable so as to
withstand the many uncertainties likely to occur both
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before and after transplantation. The contraindications
for heart transplantation are shown in Table 17.
Besides shortage of donor hearts, the main problem of
heart transplantation is rejection of the allograft, which
is responsible for a considerable percentage of deaths in
the ﬁrst postoperative year. The long-term outcome is
limited predominantly by the consequences of immuno-
suppression (infection, hypertension, renal failure, malig-
nancy, and by transplant coronary vascular disease).102
Ventricular assist devices and artiﬁcial heart
. Current indications for left ventricular assist devices and
artiﬁcial heart includebridging to transplantation, acute
severe myocarditis, and in some patients permanent
haemodynamic support (Class of recommendation IIa,
level of evidence C).
. Left ventricular assist devices are being implanted as a
bridge to transplantation. Experience from long-term
treatment is accumulating but these devices are not
recommended for routine long-term use (Class of rec-
ommendation IIb, level of evidence B).103
Ultraﬁltration
. Ultraﬁltration may be used to treat ﬂuid overload
(pulmonary or peripheral oedema) refractory to
diuretics.104 However, in most patients with severe
heart failure, the relief is temporary.105
Choice and timing of pharmacological therapy
The choice of pharmacological therapy in the various
stages of heart failure that is caused by systolic dysfunc-
tion is displayed in Table 18. Before initiating therapy,
the correct diagnosis needs to be established and
considerations should be given to the Management
Outline presented in Table 5.
Asymptomatic left ventricular systolic dysfunction
In general, the lower the ejection fraction, the higher
the risk of developing heart failure or sudden death.
Treatment with an ACE-inhibitor is recommended in
patients with reduced LVEF if indicated by a substantial
reduction in LVEF (see section on echocardiography in
the Diagnosis section) (recommendation page 1120).
Beta-blockers should be added to the therapy in
patients with asymptomatic left ventricular dysfunction,
especially if following an acute myocardial infarction
(recommendation page 1127).
Symptomatic left ventricular systolic dysfunction:
heart failure NYHA class II (Figure 4 )
Without signs of ﬂuid retention. ACE-inhibitor (rec-
ommendation page 1126). Titrate to the target dose
used in large controlled trials (Table 8 ). Add a beta-
blocker (recommendation page 1127) and titrate to
target dosages used in large controlled trials (Table 14 ).
With signs of ﬂuid retention. Diuretics in combination
with an ACE-inhibitor followed by a beta-blocker. First,
the ACE-inhibitor and diuretic should be co-administered.
When symptomatic improvement occurs (i.e. ﬂuid
retention disappears), the optimal dose of the ACE-
inhibitor should be maintained followed by a beta-
blocker. The dose of diuretic can be adjusted based on
patient stability. To avoid hyperkalaemia, any potass-
ium-sparing diuretic should be omitted from the diuretic
regimen before introducing an ACE-inhibitor. However, an
aldosterone antagonist may be added if hypokalaemia
persists. Add a beta-blocker and titrate to target
dosages used in large controlled trials (Table 13 ).
Patients in sinus rhythm receiving cardiac glycosides
and who have improved from severe to mild heart
failure should continue cardiac glycoside therapy (rec-
ommendation page 1128) In patients who remain sympto-
matic and in patients who deteriorate, the addition
of an ARB should be considered (recommendation
page 1128).
Worsening heart failure (Figure 3 )
Frequent causes of worsening heart failure are shown in
Table 19. Patients in NYHA class III that have improved
from NYHA class IV during the preceding 6 months or
are currently NYHA class IV should receive low-dose
spironolactone (12.5–50 mg daily recommendation page
1128). Cardiac glycosides are often added. Loop diuretics
can be increased in dose, and combinations of diuretics
(a loop diuretic with a thiazide) are often helpful.
Cardiac resynchronization therapy should be considered
if there is evidence of left ventricular dyssynchrony.
Heart transplantation, coronary revascularization, aneur-
ysmectory, or valve surgery may play a limited role.
End-stage heart failure (patients who persist in
NYHA IV despite optimal treatment and proper
diagnosis (Figure 4 )
Patients should be (re)considered for heart transplan-
tation if appropriate. In addition to the pharmacological
Table 17 Contraindications for heart transplantation
. Present alcohol and/or drug abuse
. Lack of proper co-operation
. Serious mental disease which could not be properly
controlled
. Treated cancer with remission and ,5 years follow-up
. Systemic disease with multi-organ involvement
. Uncontrolled infection
. Severe renal failure (creatinine clearance ,50 ml min) or
creatinine .250 mmol/L, although some centres accept
patients on haemodialysis
. Fixed high pulmonary vascular resistance (6–8 Wood units
and mean transpulmonary gradient .15 mm Hg and
pulmonary artery systolic pressure .60 mm Hg)
. Recent thrombo embolic complication
. Unhealed peptic ulcer
. Evidence of signiﬁcant liver impairment
. Other disease with a poor prognosis
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treatments outlined in earlier sections, temporary
inotropic support (intravenous sympathomimetic agents,
dopaminergic agonists and/or phosphodiesterase agents)
can be used in end-stage heart failure, but always should
be considered as an interim approach to further treat-
ment that will beneﬁt the patient.
For patients on the waiting list for transplantation brid-
ging procedures, circulatory support with intra-aortic
balloon pumping or ventricular assist devices, haemoﬁl-
tration or dialysis may sometimes be necessary. These
should be used only in the context of a strategic plan
for the long-term management of the patient.
Palliative treatment in terminal patients should always
be considered and may include the use of opiates for the
relief of symptoms.
Management of heart failure with preserved
left ventricular ejection fraction
Although recent epidemiological studies suggest that in
the elderly, the percentage of patients hospitalized
with heart failure-like symptoms and PLVEF may be as
high as 35–45%, there is uncertainty about the
Figure 4 Pharmacological therapy of symptomatic CHF that is equally systolic left ventricular dysfunction. The algorithm should primarily be viewed as
an example of how decisions on therapy can be made depending on the progression of heart failure severity. A patient in NYHA Class II can be followed
with proposals of decision-making steps. Individual adjustments must be taken into consideration.
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prevalence of diastolic dysfunction in patients with heart
failure symptoms and a normal systolic function in the
community. There is still little evidence from clinical
trials or observational studies on how to treat heart
failure with PLVEF.
Heart failure with PLVEF and heart failure due to dias-
tolic dysfunction are not synonymous. The former diagno-
sis implies the evidence of preserved LVEF and not that
left ventricular diastolic dysfunction has been
demonstrated.
The diagnosis of isolated diastolic heart failure
requires evidence of abnormal diastolic function, which
may be difﬁcult to assess. Precipitating factors should be
identiﬁed and corrected, in particular tachy-arrhythmias
should be prevented and sinus rhythm restored whenever
possible. Rate control is important. Treatment approach
is similar to patients without heart failure.106
Pharmacological therapy of heart failure with PLVEF or
diastolic dysfunction
The following recommendations are largely speculative
because of the limited data available in patients
with PLVEF or diastolic dysfunction (in general, Class of
recommendation IIa, level of evidence C).
There is no clear evidence that patients with primary
diastolic heart failure beneﬁt from any speciﬁc drug
regimen.
(1) ACE-inhibitors may improve relaxation and cardiac
distensibility directly and may have long-term
effects through their anti-hypertensive effects and
regression of hypertrophy and ﬁbrosis.
(2) Diuretics may be necessary when episodes with ﬂuid
overload are present, but should be used cautiously
so as not to lower preload excessively and thereby
reduce stroke volume and cardiac output.
(3) Beta-blockade could be instituted to lower heart rate
and increase the diastolic ﬁlling period.
(4) Verapamil-type calcium antagonists may be used for
the same reason.107 Some studies with verapamil
have shown a functional improvement in patients
with hypertrophic cardiomyopathy.108
(5) A high dose of an ARB may reduce hospitalizations.109
Heart failure treatment in the elderly
Heart failure occurs predominantly among elderly patients
with a median age of about 75 years in community studies.
Ageing is frequently associated with co-morbidity.
Frequent concomitant diseases are hypertension, renal
failure, obstructive lung disease, diabetes, stroke, arth-
ritis, and anaemia. Such patients also receive multiple
drugs, which includes the risk of unwanted interactions
and may reduce compliance. In general, these patients in
general have been excluded from randomized trials. Relief
of symptoms rather than prolongation of life may be the
most important goal of treatment for many older patients.
ACE-inhibitors and ARBs
ACE-inhibitors and ARBs are effective and well-tolerated
in elderly patients in general.
Diuretic therapy
In the elderly, thiazides are often ineffective because of
reduced glomerular ﬁltration rate. In elderly patients,
hyperkalaemia is more frequently seen with a combi-
nation of aldosterone antagonsist and ACE-inhibitors or
NSAIDs and coxibs.
Beta-blockers
Beta-blocking agents are surprisingly well tolerated in
the elderly if patients with such contraindications as
sick sinus node, AV-block and obstructive lung disease
are excluded. Beta-blockade should not be withheld
because of increasing age alone.
Cardiac glycosides
Elderly patients may be more susceptible to adverse
effects of digoxin. Initially, low dosages are recom-
mended in patients with elevated serum creatinine.
Vasodilator agents
Venodilating drugs, such as nitrates and the arterial
dilator hydralazine and the combination of these drugs,
should be administered carefully because of the risk of
hypotension.
Table 19 Most frequent causes of worsening heart failure
Non-cardiac
. Non-compliance to the prescribed regimen (salt, liquid,
medication)
. Recently co-prescribed drugs (anti-arrhythmics other than
amiodarone, beta-blockers, NSAIDs, verapamil, diltiazem)
. Infection
. Alcohol abuse








. Other supraventricular or ventricular arrhythmias
. Bradycardia
. Myocardial ischaemia (frequently symptomless), including
myocardial infarction
. Appearance or worsening of mitral or tricuspid
regurgitation
. Excessive preload reduction (e.g. due to diuretics þ
ACE-inhibitors/nitrates)
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. It is essential to recognize and correct precipitating
factors for arrhythmias, improve cardiac function and
reduce neuro-endocrine activation with beta-blockade,
ACE inhibition, and possibly, aldosterone receptor
antagonists (Class of recommendation I, level of evi-
dence C).
Ventricular arrhythmias
. In patients with ventricular arrhythmias, the use of
anti-arrhythmic agents is only justiﬁed in patients
with severe, symptomatic, sustained ventricular tachy-
cardias and where amiodarone should be the preferred
agent (Class of recommendation IIa, level of evidence
B).87,89
. ICD implantation is indicated in patients with heart
failure and with life threatening ventricular arrhyth-
mias (i.e. ventricular ﬁbrillation or sustained ventricu-
lar tachycardia) and in selected patients at high risk of
sudden death (Class of recommendation I, level of
evidence A).95,96,110–112
Atrial ﬁbrillation
. For persistent (non-self-terminating) atrial ﬁbrillation,
electrical cardioversion could be considered, although
its success rate may depend on the duration of atrial
ﬁbrillation and left atrial size (Class of recommen-
dation IIa, level of evidence B).
. In patients with atrial ﬁbrillation and heart failure and/
or depressed left ventricular function, the use of anti-
arrhythmic therapy to maintain sinus rhythm should be
restricted to amiodarone (Class of recommendation I,
level of evidence C) and, if available, to dofetilide
(Class of recommendation IIa, level of evidence B).113
. In asymptomatic patients beta-blockade, digitalis
glycosides or the combination may be considered for
control of ventricular rate (Class of recommendation
I, level of evidence B). In symptomatic patients with
systolic dysfunction digitalis glycosides are the ﬁrst
choice (Class of recommendation IIa, level of evidence
C). In PLVEF, verapamil can be considered (Class of rec-
ommendation IIa, level of evidence C).
. Anti-coagulation in persistent atrial ﬁbrillation with
warfarin should always be considered unless con-
traindicated (Class of recommendation I, level of
evidence C).
. Management of acute atrial ﬁbrillation is not depend-
ing on previous heart failure or not. Treatment strategy
is depending on symptoms and haemodynamic stability.
For options see.106
Symptomatic systolic left ventricular
dysfunction and concomitant angina or
hypertension
Speciﬁc recommendations in addition to general treat-
ment for heart failure because of systolic left ventricular
dysfunction. If angina is present
(1) optimize existing therapy, e.g. beta-blockade
(2) add long-acting nitrates
(3) if not successful, add amlodipine or felodipine
(4) consider coronary revascularization.
If hypertension is present
. optimize the dose of ACE-inhibitors, beta-blocking
agents, and diuretics.40
. add spironolactone or ARBs if not present already
. if not successful, try second generation dihydropyridine
derivatives.
Care and follow-up
See also Table 20.
. An organized system of specialist heart failure care
improves symptoms and reduces hospitalizations (Class
of recommendation I, level of evidence A) and mortality
(Class of recommendation IIa, level of evidence B) of
patients with heart failure.71,114–118
. It is likely that the optimal model will depend on local
circumstances and resources and whether the model is
designed for speciﬁc sub-groups of patients (e.g. sever-
ity of heart failure, age, co-morbidity, and left ventri-
cular systolic dysfunction) or the whole heart failure
population (Class of recommendation I, level of evi-
dence C).119–122
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